{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:21:59Z","timestamp":1780104119778,"version":"3.54.0"},"reference-count":60,"publisher":"American Society for Clinical Investigation","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,22]]},"abstract":"<jats:p>Transgenic expression of key myelosupportive human cytokines in immune-deficient mice corrects for the lack of cross-species activities of stem cell factor (SCF), IL-3, and GM-CSF. When engrafted with human umbilical cord blood (UCB), these triple-transgenic mice produce BM and spleen grafts with much higher myeloid composition, relative to nontransgenic controls. Shortly after engraftment with UCB, these mice develop a severe, fatal macrophage activation syndrome (MAS) characterized by a progressive drop in rbc numbers, increased reticulocyte counts, decreased rbc half-life, progressive cytopenias, and evidence of chronic inflammation, including elevated human IL-6. The BM becomes strikingly hypocellular, and spleens are significantly enlarged with evidence of extramedullary hematopoiesis and activated macrophages engaged in hemophagocytosis. This manifestation of MAS does not respond to lymphocyte-suppressive therapies such as steroids, i.v. immunoglobulin, or antibody-mediated ablation of human B and T cells, demonstrating a lymphocyte-independent mechanism of action. In contrast, elimination of human myeloid cells using gemtuzumab ozogamicin (anti-CD33) completely reversed the disease. Additionally, the IL-6R antibody tocilizumab delayed progression and prolonged lifespan. This new model of MAS provides an opportunity for investigation of the mechanisms driving this disease and for the testing of directed therapies in a humanized mouse.<\/jats:p>","DOI":"10.1172\/jci.insight.88181","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T11:01:06Z","timestamp":1474455666000},"source":"Crossref","is-referenced-by-count":48,"title":["A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti\u2013IL-6R treatment"],"prefix":"10.1172","volume":"1","author":[{"given":"Mark","family":"Wunderlich","sequence":"first","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-8902","authenticated-orcid":true,"given":"Courtney","family":"Stockman","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Devarajan","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Ravishankar","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish R.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children\u2019s Hospital Medical Center (CCHMC), Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mizukawa","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Mulloy","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000381996.69261.71"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.85.5.421"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.22416"},{"issue":"5","key":"B4","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"B5","first-page":"1414","article-title":"Haemophagocytic syndrome in rheumatic patients. A systematic review","volume":"16","author":"Atteritano","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.03.002"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834dd37e"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.10.001"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3413"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305979"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501035"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43157"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.200900009"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00239","article-title":"Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein","volume":"3","author":"Chiossone","year":"2012","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-684399"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.6477"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0516"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0207"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.204"},{"issue":"5","key":"B20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2012-09-456566","article-title":"Enhanced normal short-term human myelopoiesis in mice engineered to express human-specific myeloid growth factors","volume":"121","author":"Miller","year":"2013","journal-title":"Blood"},{"issue":"10","key":"B21","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2015.0289"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301507"},{"issue":"2","key":"B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.leu.2403222","article-title":"NOD\/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration","volume":"18","author":"Nicolini","year":"2004","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556340"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24188"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31824e8d9b"},{"issue":"11","key":"B28","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"B30","article-title":"Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis [published online ahead of print March 12, 2015].","author":"Rios-Fernandez","journal-title":"Am J Ther"},{"issue":"10","key":"B31","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V95.10.3102","article-title":"beta2 microglobulin-deficient (B2m(null)) NOD\/SCID mice are excellent recipients for studying human stem cell function","volume":"95","author":"Kollet","year":"2000","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1081"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-602946"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04273.x"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002326"},{"key":"B36","article-title":"Cytokine profiles in Mycoplasma pneumoniae infection-associated hemophagocytic lymphohistiocytosi","volume":"pii","author":"Yasutomi","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.37958"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3089"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264218"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90136-X"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.3.2090"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.6.364"},{"issue":"7","key":"B43","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.161.7.3639","article-title":"Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice","volume":"161","author":"Campbell","year":"1998","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/CE.S39770","article-title":"Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis","volume":"9","author":"Di Franco","year":"2014","journal-title":"Core Evid"},{"issue":"1","key":"B45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.19.11354"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118574"},{"issue":"8","key":"B48","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood.V87.8.3203.bloodjournal8783203","article-title":"Xenogeneic expression of human stem cell factor in transgenic mice mimics codominant c-kit mutations","volume":"87","author":"Majumdar","year":"1996","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353201"},{"issue":"6","key":"B50","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V94.6.1915","article-title":"The presence of novel amino acids in the cytoplasmic domain of stem cell factor results in hematopoietic defects in Steel(17H) mice","volume":"94","author":"Kapur","year":"1999","journal-title":"Blood"},{"issue":"3","key":"B51","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V91.3.879","article-title":"Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis","volume":"91","author":"Kapur","year":"1998","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.11.046"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011445"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5771"},{"key":"B55","first-page":"349","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Shetty","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"issue":"6","key":"B59","first-page":"459","article-title":"The incidence of macrophage activation syndrome in children with rheumatic disorders","volume":"63","author":"Moradinejad","year":"2011","journal-title":"Minerva Pediatr"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140288"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/88181\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:22:46Z","timestamp":1779200566000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/88181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":60,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2016,9,22]]}},"alternative-id":["10.1172\/jci.insight.88181"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.88181","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]},"article-number":"e88181"}}